U.S. markets close in 3 hours 22 minutes
  • S&P 500

    4,216.66
    +50.21 (+1.21%)
     
  • Dow 30

    33,782.37
    +492.29 (+1.48%)
     
  • Nasdaq

    14,135.66
    +105.29 (+0.75%)
     
  • Russell 2000

    2,279.42
    +41.68 (+1.86%)
     
  • Crude Oil

    73.36
    +1.72 (+2.40%)
     
  • Gold

    1,783.20
    +14.20 (+0.80%)
     
  • Silver

    26.01
    +0.05 (+0.18%)
     
  • EUR/USD

    1.1920
    +0.0055 (+0.46%)
     
  • 10-Yr Bond

    1.4770
    +0.0270 (+1.86%)
     
  • GBP/USD

    1.3922
    +0.0113 (+0.82%)
     
  • USD/JPY

    110.1650
    +0.0150 (+0.01%)
     
  • BTC-USD

    32,217.60
    -2,439.23 (-7.04%)
     
  • CMC Crypto 200

    783.81
    -66.53 (-7.82%)
     
  • FTSE 100

    7,062.29
    +44.82 (+0.64%)
     
  • Nikkei 225

    28,010.93
    -953.15 (-3.29%)
     

Prothena to Report First Quarter 2021 Financial Results on May 11th

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

DUBLIN, Ireland, May 04, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, announced today that it will report its first quarter 2021 financial results on Tuesday, May 11, 2021 after the close of the U.S. financial markets.

Consistent with past practice, the Company will not be conducting a conference call in conjunction with this financial results release on May 11.

About Prothena

Prothena Corporation plc is a late-stage clinical company with expertise in protein dysregulation and a pipeline of novel investigational therapeutics with the potential to change the course of devastating rare peripheral amyloid and neurodegenerative diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a number of other neurodegenerative diseases. For more information, please visit the Company’s website at www.prothena.com and follow the Company on Twitter @ProthenaCorp.

Contacts:

Media & Investors
Jennifer Zibuda, Director, Investor Relations & Communications
650-837-8535, jennifer.zibuda@prothena.com